Photo-based exploration of hope in young people receiving phase 1/2 cancer therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, longitudinal qualitative project that uses participant-generated photo-elicitation interviews and semi-structured interviews with clinicians and caregivers to capture how hope changes over time for young people receiving phase 1/2 cancer therapy. Participants will be guided to select 1–5 photos before each interview to prompt discussion about what they are hoping for, what sustains or challenges hope, and what they want others to understand. Focus groups with patients, caregivers, and clinicians will identify strengths, weaknesses, opportunities, and threats to hope and will be used to co-design a stakeholder-driven supportive intervention. The study does not test an intervention; findings are intended to inform future intervention development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient participants must

* Be 12 to 25 years of age.

AND

* Have a primary cancer diagnosis that is relapsed, refractory, or without curative standard-of-care options as follows:

  * 'Relapsed' disease is defined as disease recurrence following a prior complete or partial response to initial therapy.
  * 'Refractory' disease is defined as failure to achieve remission or response with standard upfront therapy.
  * Diagnoses will be considered 'without curative standard of care options' if there is no evidence-based curative treatment regimen or where standard therapies offer only palliative or non-curative intent (based on the assessment of the primary attending or division tumor board).

AND

* Be enrolled OR planning to enroll in a phase 1 or phase 2 trial for cancer-directed therapy.\* Patients will remain eligible until 4 weeks after they begin trial therapy, after which they are no longer eligible unless they subsequently enroll on a different clinical trial.

Caregiver participants must

* Be a parent or primary caregiver to a child of any age who

  * Has a primary cancer diagnosis that is relapsed, refractory, or without curative standard-of-care options

AND

* Is enrolled OR planning to enroll on a phase 1 or phase 2 trial for cancer-directed therapy.\* Parents will remain eligible until 4 weeks after their child begins trial therapy, after which they are no longer eligible unless their child subsequently enrolls on a different clinical trial.

  * Be ≥ 18 years of age or legally emancipated

Medical clinician participants (Primary Objectives 1-2) must

* Be a physician, advanced practice provider, or nurse providing direct patient care to the patient participant and/or to the child of the caregiver participant.

Psychosocial clinician participants (Primary Objective 2 only) must

* Be a psychosocial clinician (e.g., social worker, psychologist, chaplain, child life specialist, music therapist, cultural navigator, etc.)

AND

* Provide direct or consultative care to pediatric or adolescent/young adult patients with relapsed, refractory, or high-risk cancer and/or their families.

Exclusion Criteria:

Patients, Caregivers, and Clinicians will be excluded if they:

* Do not meet inclusion criteria.
* Decline, refuse, or are unwilling to participate.
* Are a minor without a legal guardian available or willing to provide informed consent.
* Lack the cognitive, communicative, or physical capacity to meaningfully participate in a photo-narrative interview, as determined by the research team in consultation with the patient, caregiver, and primary oncology team. This includes, but is not limited to, individuals with profound neurocognitive impairment, non-responsiveness, or other conditions that preclude the ability to engage in basic reflection, expression, or shared conversation about images.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Alexandra Superdock, MD — St. Jude Children's Research Hospital
• Study coordinator: Alexandra Superdock, MD
• Email: referralinfo@stjude.org
• Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How probiotics affect survival, treatment response, and gut microbiota during cancer therapy

  This test will see if taking a probiotic supplement during cancer treatment helps adults with cancer live longer, respond better to therapy, or have healthier gut bacteria.

  Recruiting Chang Gung Memorial Hospital · New Taipei City · NCT06998823

• Maintenance therapy for colorectal cancer patients after liver surgery

  This study is testing if adding maintenance therapy to standard chemotherapy can help colorectal cancer patients with liver metastases live longer without their cancer getting worse after surgery.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT05797077

• Walking exercise to reduce fatigue in older breast cancer survivors

  This study is testing whether two types of walking exercises can help older women who have survived breast cancer feel less tired.

  Recruiting University of Florida · Gainesville, Florida · NCT05684367

• Using Sacubitril/Valsartan to prevent heart damage in breast cancer treatment

  This study is testing if the medication Sacubitril/Valsartan can help protect the hearts of women undergoing treatment for breast cancer from damage.

  Recruiting at 3 sites Phase 4 Silesian Centre for Heart Diseases · Opole, Opole Voivodeship and 3 other locations · NCT05465031

• Registry for patients receiving proton therapy

  This study is creating a registry to gather information from patients receiving proton therapy for cancer to see how well the treatment works and who benefits the most.

  Recruiting at 2 sites Clinica Universidad de Navarra, Universidad de Navarra · Pamplona, Navarre and 1 other locations · NCT05151952

• Registry for patients receiving proton radiation therapy

  This study is collecting information from patients who receive proton radiation therapy to see how well it works and who benefits the most from it.

  Recruiting at 4 sites Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia and 3 other locations · NCT04376229

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.